ArticlemBio2017
Mechanisms of Resistance to Folate Pathway Inhibitors in
Open access · goldAbstract read
In one paragraph
Article in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 70 citations in OpenAlex.
- Evolutionary Convergence on a Dihydrofolate Reductase Mutation Drives Trimethoprim-Sulfamethoxazole Resistance in Burkholderia thailandensis.ACS infectious diseases · 2026Article
- Article
- Concurrent resistance and virulence traits in extremely drug-resistant Burkholderia pseudomallei from bovine milk samples: potential for zoonotic transmission.Veterinary research communications · 2026Article
- A Novel Virulent Clinical Isolate of Burkholderia pseudomallei Imported from Thailand Exhibiting Resistance to Trimethoprim-Sulfamethoxazole.The American journal of tropical medicine and hygiene · 2025Article
- Co-isolation of genetically distinct Burkholderia pseudomallei strains from a single patient in North Queensland.PloS one · 2025Article
- Multilocus sequence typing of clinical Burkholderia pseudomallei isolates from Cambodia.PLoS neglected tropical diseases · 2024Article
- Burkholderia pseudomallei and melioidosis.Nature reviews. Microbiology · 2024Review
- Convergence of Hypervirulence and Multidrug-Resistance inInfection and drug resistance · 2024Article
- Crystal structures of multidrug efflux transporters fromProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Antibiotic susceptibility of clinicalAntimicrobial agents and chemotherapy · 2023Article
- Comparison of Antimicrobial Resistance among CommensalAntibiotics (Basel, Switzerland) · 2023Article
- Expression of virulence and antimicrobial related proteins in Burkholderia mallei and Burkholderia pseudomallei.PLoS neglected tropical diseases · 2023Article
- Effective Therapeutic Options for Melioidosis: Antibiotics versus Phage Therapy.Pathogens (Basel, Switzerland) · 2022Review
- Evaluation of Delafloxacin against a Burkholderia pseudomallei Efflux Mutant Panel.Microbiology spectrum · 2022Article
- Highly specific and sensitive detection of Burkholderia pseudomallei genomic DNA by CRISPR-Cas12a.PLoS neglected tropical diseases · 2022Article
- Antimicrobial Peptides: From Design to Clinical Application.Antibiotics (Basel, Switzerland) · 2022Review
- Detecting Genetic Variation of ColonizingFrontiers in bioinformatics · 2022Article
- Computational protein design repurposed to explore enzyme vitality and help predict antibiotic resistance.Frontiers in molecular biosciences · 2022Article
- Antimicrobial Susceptibility of Western Hemisphere Isolates ofMicrobial drug resistance (Larchmont, N.Y.) · 2021Article
- Conservation of Resistance-Nodulation-Cell Division Efflux Pump-Mediated Antibiotic Resistance in Burkholderia cepacia Complex and Burkholderia pseudomallei Complex Species.Antimicrobial agents and chemotherapy · 2021Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 6 institutions in 3 countries.
Nicole L PodneckyDepartment of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA.
Katherine A RhodesDepartment of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA.
Takehiko MimaDepartment of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA.
Heather R DrewDepartment of Molecular Genetics and Microbiology, College of Medicine, Emerging Pathogens Institute, Institute for Therapeutic Innovation, University of Florida, Gainesville, Florida, USA.
Sunisa ChirakulDepartment of Molecular Genetics and Microbiology, College of Medicine, Emerging Pathogens Institute, Institute for Therapeutic Innovation, University of Florida, Gainesville, Florida, USA.
Vanaporn WuthiekanunMahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
James M SchuppTranslational Genomics Research Institute, Flagstaff, Arizona, USA.
Derek S SarovichGlobal and Tropical Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia.ORCID 0000-0002-6944-3980
Bart J CurrieGlobal and Tropical Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia.
Paul KeimTranslational Genomics Research Institute, Flagstaff, Arizona, USA.ORCID 0000-0003-0089-5820
Herbert P SchweizerDepartment of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA hschweizer@ufl.edu.
University of Florida · USColorado State University · USTranslational Genomics Research Institute · USMahidol University · THMenzies School of Health Research · AUUniversity of the Sunshine Coast · AU
Funding
Vascular stabilization as a broad theraprutic platform for biodefenseU54AI065357 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI SCHWEIZER, HERBERT P. · 2005 to 2013
$77.5MBASIC MICROBIOLOGY &INFECTIOUS DISEASEST32AI007110 · NIAID · UNIVERSITY OF FLORIDA · PI Stephanie M Karst · 1985 to 2026
$4.3MNIAID NIH HHS T32 AI007110NIAID NIH HHS U54 AI065357
Abstract
The trimethoprim and sulfamethoxazole combination, co-trimoxazole, plays a vital role in the treatment of
Indexed as
Anti-Bacterial AgentsBurkholderia pseudomalleiDrug Resistance, Multiple, BacterialFolic AcidFolic Acid AntagonistsHumansMelioidosisMetabolic Networks and PathwaysMicrobial Sensitivity TestsMutationTetrahydrofolate DehydrogenaseTrimethoprimTrimethoprim ResistanceTrimethoprim, Sulfamethoxazole Drug CombinationAnti-Bacterial AgentsFolic AcidFolic Acid AntagonistsTetrahydrofolate DehydrogenaseTrimethoprimTrimethoprim, Sulfamethoxazole Drug CombinationantibioticBurkholderiadrug resistance mechanismsefflux pumpsmelioidosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.